Ranbaxy gets Australia nod for antipsychotic drug

NEW DELHI: Ranbaxy Laboratories has received the Australian drug regulator���s nod to sell its generic version of drugmaker Janssen-Cilag���s anti-schizophrenia drug Risperdal. Australian company Janssen-Cilag specialses in psychiatry, neurology, gastrointestinal and fungal diseases.

"The company has received an approval from the Therapeutic Goods Administration (TGA), Department of Health & Ageing of the Australian government, for the registration of Ozidal Risperidone 0.5, 1, 2, 3 and 4 mg tablets in Australia. This approval was based on the assessment by the TGA that the Ranbaxy formulation of Risperidone is bioequivalent to, and having the same therapeutic effect as Risperdal, " a Ranbaxy release said on Wednesday.

With the approval of Ozidal, Ranbaxy now has 27 molecules approved for marketing in Australia covering several therapeutic areas including anti-hypertensives, anti-infectives, hypolipidaemic agents, anti-convulsants and anti-depressants, it added.